Evidence map›Paper›PMID 30806611›Full record

ArticleMicrobial genomics2019

Genomic epidemiology of severe community-onset Acinetobacter baumannii infection.

Ella M Meumann, Nicholas M Anstey, Bart J Currie, Kim A Piera, Johanna J Kenyon, Ruth M Hall, Joshua S Davis, Derek S Sarovich

Abstract read
In one paragraph

Article in Microbial genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. Lineage-specific loss of the type VI secretion system inAntimicrobial agents and chemotherapy · 2026
    Article
  3. Occurrence and Antimicrobial Resistance ofFoods (Basel, Switzerland) · 2026
    Article
  4. DiverseMicrobiology spectrum · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Structure of K102 Capsular Polysaccharide fromInternational journal of molecular sciences · 2025
    Article
  9. mBio · 2025
    Article
  10. Article
  11. TracingMicroorganisms · 2024
    Article
  12. Article
  13. Treatment and Management ofInfection and drug resistance · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Characteristics of a Carbapenem-ResistantInfection and drug resistance · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ella M Meumann1​Global and Tropical Health Division, Menzies School of Health Research, Darwin 0810, Australia.
Nicholas M Anstey1​Global and Tropical Health Division, Menzies School of Health Research, Darwin 0810, Australia.
Bart J Currie1​Global and Tropical Health Division, Menzies School of Health Research, Darwin 0810, Australia.
Kim A Piera1​Global and Tropical Health Division, Menzies School of Health Research, Darwin 0810, Australia.
Johanna J Kenyon3​School of Biomedical Sciences, Queensland University of Technology, Brisbane 4001, Australia.
Ruth M Hall4​School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.
Joshua S Davis1​Global and Tropical Health Division, Menzies School of Health Research, Darwin 0810, Australia.
Derek S Sarovich1​Global and Tropical Health Division, Menzies School of Health Research, Darwin 0810, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acinetobacter baumannii causes severe, fulminant, community-acquired pneumonia (CAP) in tropical and subtropical regions. We compared the population structure, virulence and antimicrobial resistance determinants of northern Australian community-onset A. baumannii strains with local and global strains. We performed whole-genome sequencing on 55 clinical and five throat colonization A. baumannii isolates collected in northern Australia between 1994 and 2016. Clinical isolates included CAP (n=41), healthcare-associated pneumonia (n=7) and nosocomial bloodstream (n=7) isolates. We also included 93 publicly available international A. baumannii genome sequences in the analyses. Patients with A. baumannii CAP were almost all critically unwell; 82 % required intensive care unit admission and 18 % died during their inpatient stay. Whole-genome phylogenetic analysis demonstrated that community-onset strains were not phylogenetically distinct from nosocomial strains. Some non-multidrug-resistant local strains were closely related to multidrug-resistant strains from geographically distant locations. Pasteur sequence type (ST)10 was the dominant ST and accounted for 31/60 (52 %) northern Australian strains; the remainder belonged to a diverse range of STs. The most recent common ancestor for ST10 was estimated to have occurred in 1738 (95 % highest posterior density, 1626-1826), with evidence of multiple introduction events between Australia and Southeast Asia between then and the present day. Virulence genes associated with biofilm formation and the type 6 secretion system (T6SS) were absent in many strains, and were not associated with in-hospital mortality. All strains were susceptible to gentamicin and meropenem; none carried an AbaR resistance island. Our results suggest that international dissemination of A. baumannii is occurring in the community on a contemporary timescale. Genes associated with biofilm formation and the T6SS may not be required for survival in community niches. The relative contributions of host and bacterial factors to the clinical severity of community-onset A. baumannii infection require further investigation.

Indexed as

Molecular EpidemiologyAcinetobacter baumanniiAcinetobacter InfectionsAdultAgedAnti-Bacterial AgentsAsia, SoutheasternAustraliaBiofilmsDrug Resistance, Multiple, BacterialFemaleGenes, BacterialGenetic VariationGenome, BacterialHumansIntensive Care UnitsAnti-Bacterial AgentsType VI Secretion SystemsVirulence FactorsAcinetobacter baumanniiantimicrobial resistancecommunity-acquired pneumoniaepidemiologyvirulencewhole-genome sequencing

Identifiers

PMID30806611
PMCPMC6487312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.